IP Library Granted Patent US 9,938,541
Granted Patent B2
US 9,938,541 · App. 14/649,603 · Granted Apr 10, 2018

AAV variant

Inventors: Toshikazu Nishie (Otsu, JP); Fuyuko Takashima (Kameoka, JP); Tatsuji Enoki (Kyotanabe, JP); Junichi Mineno (Uji, JP)
Assignee: TAKARA BIO INC.
C12N15/86C07K14/005C12N7/00C12N2750/14122C12N2750/14142C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,938,541
App. No.
14/649,603
Granted
Apr 10, 2018
Kind
B2
Abstract

The invention provides an AAV particle containing an adeno-associated viral (AAV) capsid protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30 of the sequence listing; a nucleic acid that encodes this capsid protein; DNA containing this nucleic acid; a cell containing this DNA; and a method for producing this cell.

Claims (18)

1. A nucleic acid encoding a variant of one or more adeno-associated virus (AAV) capsid proteins selected from the group consisting of VP1, VP2 and VP3 which contains a spacer sequence and a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30, and wherein the AAV capsid protein containing the peptide has tropism for heart and/or immune organs.

2. The nucleic acid according to claim 1 , wherein the AAV capsid protein is derived from AAV2.

3. The nucleic acid according to claim 1 , wherein the peptide is placed at a position following amino acid number 588 in VP1, a position following amino acid number 451 in VP2 or a position following amino acid number 386 in VP3.

4. A recombinant DNA comprising the nucleic acid according to claim 1 .

5. An isolated host cell comprising the nucleic acid according to claim 1 .

6. An AAV particle comprising a variant of one or more AAV capsid proteins selected from the group consisting of VP1, VP2 and VP3 which contains a spacer sequence and a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30.

7. The AAV particle according to claim 6 , wherein the AAV capsid protein is derived from AAV2.

8. The AAV particle according to claim 7 , wherein the peptide is placed at a position following amino acid number 588 in VP1, a position following amino acid number 451 in VP2 or a position following amino acid number 386 in VP3.

9. A method of producing a gene-transduced cell, the method comprising a step of bringing an AAV particle comprising a variant of one or more AAV capsid proteins selected from the group consisting of VP1, VP2 and VP3 which contains a spacer sequence and a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30 into contact with a cell.

10. The method according to claim 9 , wherein the AAV capsid protein is derived from AAV2.

11. The method according to claim 9 , wherein the peptide is placed at a position following amino acid number 588 in VP1, a position following amino acid number 451 in VP2 or a position following amino acid number 386 in VP3.

12. A recombinant DNA comprising the nucleic acid according to claim 2 .

13. A recombinant DNA comprising the nucleic acid according to claim 3 .

14. An isolated host cell comprising the nucleic acid according to claim 2 .

15. An isolated host cell comprising the nucleic acid according to claim 3 .

16. An isolated host cell comprising the recombinant DNA according to claim 4 .

17. The nucleic acid according to claim 1 , wherein the spacer sequence consists of 1 to 5 amino acid residues.

18. The nucleic acid according to claim 1 , wherein the spacer sequence comprises an amino acid selected from the group consisting of glycine, alanine and serine.

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 29, 2016
From: TAKARA BIO INC.
To: TAKARA BIO INC.
Reel/Frame 039206/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2015
From: NISHIE, TOSHIKAZU; TAKASHIMA, FUYUKO; ENOKI, TATSUJI; MINENO, JUNICHI
To: TAKARA BIO INC.
Reel/Frame 035785/0764 →
Priority Claims (1)
JP 2012-280485 · Dec 25, 2012 · national
Continuity (1)
Related Publication 20150315610A1 · Nov 5, 2015